What Happened? Shares of biotech company Amgen (NASDAQ:AMGN) jumped 3.1% in the afternoon session after the company received ...

By Puyaan Singh June 29 (Reuters) - The New England Journal of Medicine on Monday retracted an article on a pivotal clinical ...

By Jonathan Stempel July 1 (Reuters) - A federal judge on Wednesday blocked Colorado from capping the price of Amgen's ...

A clinical trial used to approve Amgen Inc.’s pill Tavneos was retracted Monday from the New England Journal of Medicine, ...

If you are wondering whether Amgen stock still offers value at current levels, this article walks through what the numbers ...

Weigh the financial strength of a pharma leader against the rapid growth, and risks, of a biotech newcomer as both navigate ...

Viridian Therapeutics has scored an FDA approval for Lumvoa to treat thyroid eye disease (TED), triggering competition with ...

Amgen recalls 934K bottles of Corlanor and Sensipar due to foreign material and manufacturing deviations, per FDA June 23 report.

Alphabet may be the Dow's newest member, but these three dividend-paying Dow stocks look like the better buys for income ...

Amgen announced 52-week results from a phase 2 trial with its weight-management candidate, MariTide. The results Amgen posted don't appear very competitive with Eli Lilly's weight management drug, ...

With a label expansion for Uplizna pushing the drug into an untouched rare disease market, Amgen is getting its money’s worth out of another drug from its $27.8 billion Horizon Therapeutics buy.

Amgen (AMGN) stock is in focus as an expert panel of the European Medicines Agency recommends withdrawal of the company's ...